Axsome Therapeutics (AXSM) received from FDA proposed labeling for AXS-05 product candidate with respect to its NDA for AXS-05 for treatment of major depressive disorder

June 27, 2022 7:17 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Axsome Therapeutics (NASDAQ: AXSM) disclosed:

On June 24, 2022, Axsome Therapeutics, Inc. (the “Company”) received from the U.S. Food and Drug Administration (the “FDA”) proposed labeling for the Company’s AXS-05 product candidate with respect to its New Drug Application (the “NDA”) for AXS-05 for the treatment of major depressive disorder. The Company is reviewing the proposed labeling and will reply to the FDA to secure final labeling agreement.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA, Hot FDA News

Related Entities